A large outbreak of extensively drug-resistant (XDR) Salmonella enterica serotype Typhi infections is ongoing in Pakistan, predominantly in Sindh Province. Here, we report the sequencing and characterization of five XDR Salmonella Typhi isolates from the Punjab province of Pakistan that are closely related to the outbreak strain and carry the same IncY plasmid.
A n outbreak of extensively drug-resistant (XDR) Salmonella enterica serotype Typhi infections is ongoing in Pakistan (1, 2) . Cases have been reported from November 2016 until the present, mostly from Sindh Province in the cities of Karachi and Hyderabad (1, 2) . The outbreak strain has been genetically characterized previously, including identification of the resistance determinants and plasmids responsible for the XDR phenotype (2) . Here, we report the sequencing and characterization of five XDR Salmonella Typhi isolates from patients in the province of Punjab in 2018.
Five isolates (Table 1) identified as XDR Salmonella Typhi at the National Institute of Health in Pakistan were subcultured on blood agar, stored in 40% glycerol Trypticase soy broth, and sent to the U.S. Centers for Disease Control and Prevention. DNA extraction was performed on cultures grown from single-colony frozen stocks on blood agar at 37°C overnight before sequencing on the Illumina MiSeq platform, as previously described (3) . Default parameters were used for all software, unless otherwise specified. Lyve-SET v.1.1.4f (4) was used for high-quality single nucleotide polymorphism (hqSNP) analysis with an external reference (GenBank accession number LT882486), using the following options: -min_coverage, 20; -min_alt_frac, 0.95; -allowedFlanking, 5 bp; and -mask-phages. SMALT v.0.7.4 (5) was used for mapping, and SNPs were called with VarScan v.2.3.7 (6) . De novo assemblies generated using shovill v.1.0.4 (https://github.com/tseemann/shovill) were analyzed for resistance determinants using the ResFinder database (90% identity, 50% cutoff) and the Point-Finder scheme for Salmonella spp. implemented in staramr v.0.4.0. Plasmid replicons were identified using abricate v.0.8.10 and a database adapted from PlasmidFinder (90% identity, 60% cutoff). Antibiotic susceptibility testing was performed at the CDC National Antimicrobial Resistance Monitoring System (NARMS) laboratory, using CLSI interpretative criteria (7) . Extracted DNA from one isolate (2018K-0756) from a 29-yearold male resident of Punjab was also sequenced by Pacific Biosciences single-molecule real-time (SMRT) technology. Reads were filtered using RS_Filter from SMRT Analysis v.2.3.0 (minsubreadlength, 1,000) and de novo assembled using FLYE v.2.4.2 (8, 9) , 1B , catA1, dfrA7, qnrS1, sul1, and sul2] . The XDR phenotype conferred by these resistance determinants was confirmed for all five isolates, namely, resistance to ampicillin, ceftriaxone, chloramphenicol, ciprofloxacin, nalidixic acid, streptomycin, sulfisoxazole, and trimethoprim-sulfamethoxazole. All contained an IncY plasmid replicon and a partial IncQ1 replicon (529 bp of the 796-bp IncQ1 replicon sequence) within the resistance region, except 2018K-0756, which lacked IncQ1. 2018K-0756 carries catA1, dfrA7, and sul1 in a chromosomally integrated IS1-mediated composite transposon at the same location as in 22420_1_10_Pak60006_2016 but lacks a 7,857-bp internal region containing the partial IncQ1 replicon, aph(3Љ)-Ib, aph(6)-Id, bla TEM-1B , and sul2. The IncY plasmid from 2018K-0756 (p2018K-0756) carries aph(3Љ)-Ib, aph(6)-Id, bla CTX-M-15 , bla TEM-1B , qnrS1, and sul2 and is 99.99% identical (5 SNPs) to that from 22420_1_10_Pak60006_2016 (p60006) (GenBank accession number LT906492).
Data availability. The sequences discussed here have been deposited in GenBank and SRA under the accession and BioSample numbers listed in Table 1 . 
